Valuation : Emergent BioSolutions Inc.

Market Cap 331M 286M 269M 245M 458M 31.29B 462M 3.19B 1.24B 16B 1.24B 1.22B 52.55B P/E 2026 *
-1.39x
P/E 2027 * 97.3x
Enterprise Value 701M 605M 570M 519M 971M 66.26B 978M 6.75B 2.62B 33.87B 2.63B 2.58B 111B EV / Sales 2026 *
1.07x
EV / Sales 2027 * 0.91x
Free-Float
43.38%
Yield 2026 *
-
Yield 2027 * -
1 day-4.88%
1 week+4.21%
Current month+1.48%
1 month-16.46%
3 months-21.94%
6 months-30.61%
Current year-49.92%
1 week 5.8
Extreme 5.8
6.6
1 month 4.36
Extreme 4.36
7.7
Current year 4.36
Extreme 4.36
14.06
1 year 4.36
Extreme 4.36
14.06
3 years 1.42
Extreme 1.42
15.1
5 years 1.42
Extreme 1.42
63.33
10 years 1.42
Extreme 1.42
137.61
Manager TitleAgeSince
Chief Executive Officer 70 21/02/2024
Director of Finance/CFO 62 26/03/2018
Compliance Officer 55 01/03/2020
Director TitleAgeSince
Chairman 82 01/04/2022
Director/Board Member 70 01/01/2005
Director/Board Member 77 01/10/2016
Date Insider Type Main position Quantity % Market Cap. Importance
8/5/26 A Other

Executive/Senior Manager

455,311 0.8824%
7/1/26 A Sell

Executive/Senior Manager

-3,000 0.0058%
5/1/26 A Sell

Director

-13,761 0.0266%
Change 5-day change 1-year change 3-year change Capi.($)
-4.88%+4.21%-20.95%+28.42% 331M
-0.56%-1.85%+56.45%+106.80% 1,034B
+0.95%+4.75%+56.41%+73.27% 663B
-0.34%+1.01%+23.09%+78.49% 462B
+2.09%-2.06%+32.28%+38.37% 344B
0.00%+5.36%+27.40%+47.50% 307B
+1.42%+0.26%-0.52%+13.62% 251B
+0.09%+1.42%+56.14%+74.48% 239B
-0.03%+2.13%-17.30%-53.99% 207B
+0.36%+0.87%+32.90%+99.79% 186B
Average +0.06%+0.19%+24.59%+50.67% 369.37B
Weighted average by Cap. +0.43%-0.84%+38.39%+68.14%

Financials

2026 *2027 *
Net sales 657M 567M 534M 487M 909M 62.08B 916M 6.32B 2.45B 31.74B 2.47B 2.41B 104B 703M 607M 572M 521M 973M 66.44B 981M 6.77B 2.63B 33.97B 2.64B 2.58B 112B
Net income -239M -206M -194M -177M -331M -22.6B -334M -2.3B -893M -11.55B -898M -879M -37.95B 3.48M 3M 2.82M 2.57M 4.81M 328M 4.85M 33.44M 12.98M 168M 13.05M 12.77M 551M
Net Debt 370M 319M 301M 274M 512M 34.97B 516M 3.56B 1.38B 17.88B 1.39B 1.36B 58.73B 309M 266M 251M 229M 427M 29.18B 431M 2.97B 1.15B 14.92B 1.16B 1.13B 49B
Logo Emergent BioSolutions Inc.
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Employees
900
Date Price Change Volume
03/09/26 $6.180 -4.33% 253,428
02/09/26 $6.460 +3.86% 1,034,061
01/09/26 $6.220 +1.97% 972,440
31/08/26 $6.100 +3.21% 1,126,461
28/08/26 $5.910 -0.51% 1,244,042
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.460USD
Average target price
11.00USD
Spread / Average Target
+70.28%

Quarterly revenue - Rate of surprise